BriaCell Therapeutics Corp

Company Profile

BriaCell Therapeutics Corp had its IPO on 2021-02-24 under the ticker symbol BCTXW.

The company operates in the sector and industry. BriaCell Therapeutics Corp has a staff strength of 0 employees.

Stock update

Shares of BriaCell Therapeutics Corp opened at $2.4 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.31 - $2.48, and closed at $2.48.

This is a +1.64% increase from the previous day's closing price.

A total volume of 22,745 shares were traded at the close of the day’s session.

In the last one week, shares of BriaCell Therapeutics Corp have slipped by -6.42%.

BriaCell Therapeutics Corp's Key Ratios

BriaCell Therapeutics Corp has a market cap of $48.08 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months BriaCell Therapeutics Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-3742391. The EBITDA ratio measures BriaCell Therapeutics Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, BriaCell Therapeutics Corp’s operating margin was 0% while its return on assets stood at -382.02% with a return of equity of 0%.

In Q4, BriaCell Therapeutics Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

BriaCell Therapeutics Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BriaCell Therapeutics Corp’s profitability.

BriaCell Therapeutics Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

BriaCell Therapeutics Corp stock pays annual dividends of $ per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$34.16 million

Total Liabilities

$670413.00

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

BriaCell Therapeutics Corp ended 2024 with $34.16 million in total assets and $0 in total liabilities. Its intangible assets were valued at $34.16 million while shareholder equity stood at $-1280586.00.

BriaCell Therapeutics Corp ended 2024 with $0 in deferred long-term liabilities, $670413.00 in other current liabilities, 65589293.00 in common stock, $-73338140.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.50 million and cash and short-term investments were $33.50 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

BriaCell Therapeutics Corp’s total current assets stands at $33.94 million while long-term investments were $2.00 and short-term investments were $0. Its net receivables were $8928.00 compared to accounts payable of $582451.00 and inventory worth $0.

In 2024, BriaCell Therapeutics Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, BriaCell Therapeutics Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$2.48

52-Week High

$3.9881

52-Week Low

$1.603

Analyst Target Price

$

BriaCell Therapeutics Corp stock is currently trading at $2.48 per share. It touched a 52-week high of $3.9881 and a 52-week low of $3.9881. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $2.54 and 200-day moving average was $2.65 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.